Cell Culture Engineering (Advances in Biochemical Engineering/Biotechnology, nr. 101)

Editat de Wei-Shu Hu
Notă GoodReads:
en Limba Engleză Hardback – 23 Aug 2006
Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade.
Citește tot Restrânge
Toate formatele și edițiile
Toate formatele și edițiile Preț Express
Paperback (1) 113816 lei  50-64 zile +81104 lei  11-19 zile
  Springer Berlin, Heidelberg – 18 Nov 2010 113816 lei  50-64 zile +81104 lei  11-19 zile
Hardback (1) 155669 lei  50-64 zile +103400 lei  11-19 zile
  Springer Berlin, Heidelberg – 23 Aug 2006 155669 lei  50-64 zile +103400 lei  11-19 zile

Din seria Advances in Biochemical Engineering/Biotechnology

Preț: 155669 lei

Preț vechi: 167386 lei

Puncte Express: 2335

Preț estimativ în valută:
30103 31358$ 25885£

Carte tipărită la comandă

Livrare economică 16-30 ianuarie 23
Livrare express 08-16 decembrie pentru 104399 lei

Preluare comenzi: 021 569.72.76


ISBN-13: 9783540340065
ISBN-10: 3540340068
Pagini: 184
Ilustrații: XI, 168 p.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.44 kg
Ediția: 2006
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Advances in Biochemical Engineering/Biotechnology

Locul publicării: Berlin, Heidelberg, Germany

Public țintă



S.S. Farid: Established Bioprocesses for Producing Antibodies as a Basis for Future Planning.- K.F. Wlaschin, W.-S. Hu: Fedbatch Culture and Dynamic Nutrient Feeding.- K. Konstantinov, C. Goudar, M. Ng, R. Meneses, J. Thrift, S. Chuppa, C. Matanguihan, J. Michaels, D. Naveh: The 'Push-To-Low' Approach for Optimitzation of High-Density Perfusion Cultures of Animal Cells.- C. Goudar, R. Biener, C. Zhang, J. Michaels, J. Piret, K. Konstantinov: Towards Industrial Application of Quasi Real-Time Metabolic Flux Analysis for Mammalian Cell Culture.- G. Seth, P. Hossler, J.C. Yee, W.-S. Hu: Engineering Cells for Cell Culture Bioprocessing-Physiological Fundamentals.-


Covers trends in modern biotechnology
All aspects of this interdisciplinary technology, where knowledge, methods and expertise are required from chemistry, biochemistry, microbiology, genetics, chemical engineering and computer science, are treated
More information as well as the electronic version available at